Fox Jennifer Lynne 4

What Happened Jennifer Lynne Fox, Chief Legal Officer of Myriad Genetics (MYGN), was granted 195,876 restricted stock units (RSUs) on 2026-03-12 (transaction code A). The RSUs have no purchase price (reported $0.00) and represent contingent rights to receive shares. On 2026-03-13 the issuer withheld 5,995 shares to satisfy tax withholding obligations (transaction code F) at $4.66 per share, a disposition valued at $27,937.

Key Details

• Grant date: 2026-03-12 — 195,876 RSUs granted (acquisition at $0.00, code A).
• Tax withholding: 2026-03-13 — 5,995 shares withheld @ $4.66 each, total ≈ $27,937 (code F). The withholding was done by the issuer to cover taxes.
• Vesting: RSUs vest in three equal annual installments beginning on the first anniversary of the grant (per footnote F1).
• Valuation note: Using the March 13 closing price cited for withholding ($4.66), the grant’s approximate market value would be roughly $912,800.
• Shares owned after the transactions: not specified in the Form 4.
• Timeliness: Filing dated 2026-03-16; the Form 4 was filed within the SEC’s reporting window (not late).

Context RSU grants are awards, not open-market purchases, and reflect compensation rather than a direct buy signal. The 5,995-share disposition was a routine issuer withholding to satisfy tax obligations on vested RSUs (not an open-market sale by the insider). The RSUs vest over time, so additional shares may be delivered on future anniversaries per the stated schedule.